prospective randomized trial of the European MCL Network prolongs progression-free survival in mantle-cell lymphoma : results of a autologous stem cell transplantation in first remission significantly Early consolidation by myeloablative radiochemotherapy followed

Parwaresch, Michael Unterhalt and Wolfgang Hiddemann Boogaerts, Ali Aldaoud, Vittorio Silingardi, Hanneke C. Kluin-Nelemans, Joerg Hasford, Reza Bernd Metzner, Lorenz Truemper, Marcel Reiser, Hjalmar Steinhauer, Jean-Michel Boiron, Marc A. Martin Dreyling, Georg Lenz, Eva Hoster, Achiel Van Hoof, Christian Gisselbrecht, Rudolf Schmits, prospective randomized trial of the European MCL Network prolongs progression-free survival in mantle-cell lymphoma: results of a autologous stem cell transplantation in first remission significantly Early consolidation by myeloablative radiochemotherapy followed by

[1]  C. Moskowitz.  Mantle cell lymphomas. , 2005, Clinical advances in hematology & oncology : H&O.

[2]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Hiddemann,et al.  Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Diehl,et al.  Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. , 2004, Blood.

[5]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Sydes,et al.  High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Franssila,et al.  Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant , 2003, European journal of haematology.

[8]  T. Barbui,et al.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). , 2003, Blood.

[9]  D. Weisenburger,et al.  Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries , 2003, British journal of haematology.

[10]  S. A. Bush,et al.  High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. , 2002, Blood.

[11]  R. Bouabdallah,et al.  Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study , 2002, Leukemia.

[12]  J. Gribben,et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Arcaini,et al.  A sequence of immuno‐chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high‐dose chemotherapy and autotransplant is an effective 
and non‐toxic treatment for advanced follicular 
and mantle cell lymphoma , 2002, British journal of haematology.

[14]  M. Gobbi,et al.  Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Kantarjian,et al.  Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients , 2000, Leukemia & lymphoma.

[16]  N. Schmitz,et al.  The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. , 2000, The hematology journal : the official journal of the European Haematology Association.

[17]  B. Coiffier,et al.  Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Pileri,et al.  Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. , 2000, Blood.

[19]  H. Kantarjian,et al.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Moreau,et al.  High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience , 1998, Bone Marrow Transplantation.

[21]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[22]  M. Tiemann,et al.  Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Gribben,et al.  High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Pittaluga,et al.  The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non‐intensive therapy by the British National Lymphoma Investigation Group , 1997, British journal of haematology.

[25]  G. Salles,et al.  Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  G. Brittinger,et al.  Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. , 1996, Leukemia.

[27]  W Hiddemann,et al.  Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. , 1996, Leukemia.

[28]  E. Noordijk,et al.  Mantle-cell lymphoma: a population-based clinical study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[30]  A. Hagenbeek,et al.  Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Weisenburger,et al.  The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  F. Cavalli,et al.  Patterns of survival in mantle cell lymphoma. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.